Advanced search
Add to list

SF3B1 mutations and outcome in CLL patients treated with chlorambucil (CHL) or ofatumumab-CHL (O plus CHL): results from the phase III study complement 1 (OMB110911)

(2014) HAEMATOLOGICA. 99(suppl. 1). p.522-523
Author
Organization

Citation

Please use this url to cite or link to this publication:

MLA
Tausch, E, C Galler, RF Schlenk, et al. “SF3B1 Mutations and Outcome in CLL Patients Treated with Chlorambucil (CHL) or ofatumumab-CHL (O Plus CHL): Results from the Phase III Study Complement 1 (OMB110911).” Haematologica. Vol. 99. 2014. 522–523. Print.
APA
Tausch, E, Galler, C., Schlenk, R., Hillmen, P., Offner, F., Janssens, A., Govindbabu, K., et al. (2014). SF3B1 mutations and outcome in CLL patients treated with chlorambucil (CHL) or ofatumumab-CHL (O plus CHL): results from the phase III study complement 1 (OMB110911). HAEMATOLOGICA (Vol. 99, pp. 522–523). Presented at the 19th Congress of the European Hematology Association (EHA).
Chicago author-date
Tausch, E, C Galler, RF Schlenk, P Hillmen, Fritz Offner, A Janssens, K Govindbabu, et al. 2014. “SF3B1 Mutations and Outcome in CLL Patients Treated with Chlorambucil (CHL) or ofatumumab-CHL (O Plus CHL): Results from the Phase III Study Complement 1 (OMB110911).” In Haematologica, 99:522–523.
Chicago author-date (all authors)
Tausch, E, C Galler, RF Schlenk, P Hillmen, Fritz Offner, A Janssens, K Govindbabu, S Grosicki, J Mayer, P Panagiotidis, A McKeown, PD Winter, IV Gupta, H Dohner, and S Stilgenbauer. 2014. “SF3B1 Mutations and Outcome in CLL Patients Treated with Chlorambucil (CHL) or ofatumumab-CHL (O Plus CHL): Results from the Phase III Study Complement 1 (OMB110911).” In Haematologica, 99:522–523.
Vancouver
1.
Tausch E, Galler C, Schlenk R, Hillmen P, Offner F, Janssens A, et al. SF3B1 mutations and outcome in CLL patients treated with chlorambucil (CHL) or ofatumumab-CHL (O plus CHL): results from the phase III study complement 1 (OMB110911). HAEMATOLOGICA. 2014. p. 522–3.
IEEE
[1]
E. Tausch et al., “SF3B1 mutations and outcome in CLL patients treated with chlorambucil (CHL) or ofatumumab-CHL (O plus CHL): results from the phase III study complement 1 (OMB110911),” in HAEMATOLOGICA, Milan, Italy, 2014, vol. 99, no. suppl. 1, pp. 522–523.
@inproceedings{5792271,
  articleno    = {abstract S1344},
  author       = {Tausch, E and Galler, C and Schlenk, RF and Hillmen, P and Offner, Fritz and Janssens, A and Govindbabu, K and Grosicki, S and Mayer, J and Panagiotidis, P and McKeown, A and Winter, PD and Gupta, IV and Dohner, H and Stilgenbauer, S},
  booktitle    = {HAEMATOLOGICA},
  issn         = {0390-6078},
  language     = {eng},
  location     = {Milan, Italy},
  number       = {suppl. 1},
  pages        = {abstract S1344:522--abstract S1344:523},
  title        = {SF3B1 mutations and outcome in CLL patients treated with chlorambucil (CHL) or ofatumumab-CHL (O plus CHL): results from the phase III study complement 1 (OMB110911)},
  volume       = {99},
  year         = {2014},
}

Web of Science
Times cited: